The closing price of GSK Plc ADR (NYSE: GSK) was $41.54 for the day, down -0.60% from the previous closing price of $41.79. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 3048389 shares were traded.
Ratios:
Our analysis of GSK’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.53. For the most recent quarter (mrq), Quick Ratio is recorded 0.62 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 1.14.
On January 23, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $44.Morgan Stanley initiated its Equal-Weight rating on January 23, 2024, with a $44 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 07 ’23 when GSK plc bought 3,300,000 shares for $5.00 per share. The transaction valued at 16,500,000 led to the insider holds 13,983,761 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GSK now has a Market Capitalization of 85.25B and an Enterprise Value of 101.59B. As of this moment, GSK’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.88, and their Forward P/E ratio for the next fiscal year is 9.34. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.23 while its Price-to-Book (P/B) ratio in mrq is 4.95. Its current Enterprise Value per Revenue stands at 3.35 whereas that against EBITDA is 11.19.
Stock Price History:
The Beta on a monthly basis for GSK is 0.67, which has changed by 9.32% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, GSK has reached a high of $43.84, while it has fallen to a 52-week low of $33.33. The 50-Day Moving Average of the stock is 41.91, while the 200-Day Moving Average is calculated to be 37.57.
Shares Statistics:
GSK traded an average of 3.53M shares per day over the past three months and 2.34M shares per day over the past ten days. A total of 2.03B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.01% of the company’s shares, while institutions hold 14.57% stake in the company. Shares short for GSK as of Mar 15, 2024 were 3.97M with a Short Ratio of 1.12, compared to 4.62M on Feb 15, 2024.
Dividends & Splits
With its trailing 12-month dividend rate of 0.58, GSK has a forward annual dividend rate of 1.47. Against a Trailing Annual Dividend Yield of 1.39%, it implies a Forward Annual Dividend Yield of 3.51%. The stock’s 5-year Average Dividend Yield is 4.97. The current Payout Ratio is 47.52% for GSK, which recently paid a dividend on Apr 11, 2024 with an ex-dividend date of Feb 22, 2024. Stock splits for the company last occurred on Jul 22, 2022 when the company split stock in a 1226:1000 ratio.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was $0.9. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $4.07 and $3.99 for the fiscal current year, implying an average EPS of $4.02. EPS for the following year is $4.54, with 3 analysts recommending between $4.71 and $4.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $9.35B to a low estimate of $9.35B. As of the current estimate, GSK Plc ADR’s year-ago sales were $8.45B, an estimated increase of 10.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $9.53B, an increase of 6.00% less than the figure of $10.70% in the same quarter last year. There is a high estimate of $9.53B for the next quarter, whereas the lowest estimate is $9.53B.
A total of 4 analysts have provided revenue estimates for GSK’s current fiscal year. The highest revenue estimate was $40.79B, while the lowest revenue estimate was $39.81B, resulting in an average revenue estimate of $40.33B. In the same quarter a year ago, actual revenue was $37.7B, up 7.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $42.94B in the next fiscal year. The high estimate is $43.88B and the low estimate is $41.95B. The average revenue growth estimate for next year is up 6.50% from the average revenue estimate for this year.
